138 related articles for article (PubMed ID: 32164983)
1. Postnatal fate of donor mesenchymal stem cells after transamniotic stem cell therapy in a healthy model.
Tracy SA; Chalphin AV; Lazow SP; Kycia I; Finkelstein A; Chan C; Zurakowski D; Fauza DO
J Pediatr Surg; 2020 Jun; 55(6):1113-1116. PubMed ID: 32164983
[TBL] [Abstract][Full Text] [Related]
2. Donor mesenchymal stem cell linetics after transamniotic stem cell therapy (TRASCET) for experimental spina bifida.
Shieh HF; Ahmed A; Rohrer L; Zurakowski D; Fauza DO
J Pediatr Surg; 2018 Jun; 53(6):1134-1136. PubMed ID: 29580785
[TBL] [Abstract][Full Text] [Related]
3. Hematogenous Donor Cell Routing Pathway After Transamniotic Stem Cell Therapy.
Tracy SA; Chalphin AV; Kycia I; Chan C; Finkelstein A; Zurakowski D; Fauza DO
Stem Cells Dev; 2020 Jun; 29(12):755-760. PubMed ID: 32228172
[TBL] [Abstract][Full Text] [Related]
4. Transamniotic stem cell therapy (TRASCET) in a rabbit model of spina bifida.
Shieh HF; Tracy SA; Hong CR; Chalphin AV; Ahmed A; Rohrer L; Zurakowski D; Fauza DO
J Pediatr Surg; 2019 Feb; 54(2):293-296. PubMed ID: 30518492
[TBL] [Abstract][Full Text] [Related]
5. Donor mesenchymal stem cells home to maternal wounds after transamniotic stem cell therapy (TRASCET) in a rodent model.
Graham CD; Shieh HF; Brazzo JA; Zurakowski D; Fauza DO
J Pediatr Surg; 2017 Jun; 52(6):1006-1009. PubMed ID: 28363468
[TBL] [Abstract][Full Text] [Related]
6. Transamniotic stem cell therapy (TRASCET) for intrauterine growth restriction (IUGR): A comparison between placental and amniotic fluid donor mesenchymal stem cells.
Whitlock AE; Moskowitzova K; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2023 Feb; 58(2):305-309. PubMed ID: 36372622
[TBL] [Abstract][Full Text] [Related]
7. Donor mesenchymal stem cell kinetics after transamniotic stem cell therapy (TRASCET) in a rodent model of gastroschisis.
Chalphin AV; Tracy SA; Kycia I; Chan C; Finkelstein A; Zurakowski D; Fauza DO
J Pediatr Surg; 2020 Mar; 55(3):482-485. PubMed ID: 31813581
[TBL] [Abstract][Full Text] [Related]
8. Bidirectional Feto-Maternal Traffic of Donor Mesenchymal Stem Cells Following Transamniotic Stem Cell Therapy (TRASCET).
Moskowitzova K; Whitlock AE; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2024 Feb; 59(2):290-294. PubMed ID: 37945511
[TBL] [Abstract][Full Text] [Related]
9. Fetal hematogenous routing of a donor hematopoietic stem cell line in a healthy syngeneic model of transamniotic stem cell therapy.
Lazow SP; Kycia I; Labuz DF; Zurakowski D; Fauza DO
J Pediatr Surg; 2021 Jun; 56(6):1233-1236. PubMed ID: 33771370
[TBL] [Abstract][Full Text] [Related]
10. Transamniotic stem cell therapy (TRASCET) mitigates bowel damage in a model of gastroschisis.
Feng C; Graham CD; Connors JP; Brazzo J; Pan AH; Hamilton JR; Zurakowski D; Fauza DO
J Pediatr Surg; 2016 Jan; 51(1):56-61. PubMed ID: 26548631
[TBL] [Abstract][Full Text] [Related]
11. A comparison between placental and amniotic mesenchymal stem cells for transamniotic stem cell therapy (TRASCET) in experimental spina bifida.
Feng C; D Graham C; Connors JP; Brazzo J; Zurakowski D; Fauza DO
J Pediatr Surg; 2016 Jun; 51(6):1010-3. PubMed ID: 27013425
[TBL] [Abstract][Full Text] [Related]
12. A comparison between placental and amniotic mesenchymal stem cells in transamniotic stem cell therapy for experimental gastroschisis.
Chalphin AV; Tracy SA; Lazow SP; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2020 Jan; 55(1):49-53. PubMed ID: 31711742
[TBL] [Abstract][Full Text] [Related]
13. Transamniotic Fetal Administration of Genetically Modified Hematopoietic Stem Cells Carrying a Human Transgene in a Syngeneic Rat Model.
Labuz DF; Whitlock AE; Kycia I; Zurakowski D; Fauza DO
Stem Cells Dev; 2023 Apr; 32(7-8):180-184. PubMed ID: 36719776
[TBL] [Abstract][Full Text] [Related]
14. Fetal bone marrow homing of donor mesenchymal stem cells after transamniotic stem cell therapy (TRASCET).
Shieh HF; Ahmed A; Tracy SA; Zurakowski D; Fauza DO
J Pediatr Surg; 2017 Oct; ():. PubMed ID: 29132800
[TBL] [Abstract][Full Text] [Related]
15. Brain protection by transamniotic stem cell therapy (TRASCET) in a model of intrauterine growth restriction (IUGR).
Whitlock AE; Moskowitzova K; Labuz DF; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2023 Jan; 58(1):3-7. PubMed ID: 36344286
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of transamniotic stem cell therapy for spina bifida by genetic engineering of donor mesenchymal stem cells with an Fgf2 transgene.
Lazow SP; Labuz DF; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2021 Jun; 56(6):1226-1232. PubMed ID: 33771369
[TBL] [Abstract][Full Text] [Related]
17. Early functional analysis on the pulmonary hemodynamic effects of Transamniotic Stem Cell Therapy (TRASCET) in the nitrofen model of congenital diaphragmatic hernia.
Labuz DF; Whitlock AE; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2023 Jan; 58(1):8-13. PubMed ID: 36280468
[TBL] [Abstract][Full Text] [Related]
18. Routing pathway of syngeneic donor hematopoietic stem cells after simple intra-amniotic delivery.
Labuz DF; Whitlock AE; Kycia I; Zurakowski D; Fauza DO
J Pediatr Surg; 2022 Jun; 57(6):986-990. PubMed ID: 35279287
[TBL] [Abstract][Full Text] [Related]
19. Transamniotic stem cell therapy (TRASCET) in a leporine model of gastroschisis.
Feng C; Graham CD; Shieh HF; Brazzo JA; Connors JP; Rohrer L; Papadakis A; Zurakowski D; Fauza DO
J Pediatr Surg; 2017 Jan; 52(1):30-34. PubMed ID: 27836365
[TBL] [Abstract][Full Text] [Related]
20. Transamniotic Stem Cell Therapy for Experimental Congenital Diaphragmatic Hernia: Structural, Transcriptional, and Cell Kinetics Analyses in the Nitrofen Model.
Chalphin AV; Lazow SP; Labuz DF; Tracy SA; Kycia I; Zurakowski D; Fauza DO
Fetal Diagn Ther; 2021; 48(5):381-391. PubMed ID: 33853064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
